
PDS Biotechnology Investor Relations Material
Latest events

Status Update
PDS Biotechnology
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from PDS Biotechnology Corporation
Access all reports
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its product pipeline includes thermo-sensitive PDS0101 (Amiket), which is in Phase 3 clinical trials for the treatment of patients with human papillomavirus associated disease; Discovery Program, a research and discovery program with a focus on tumor neo-antigens and synthetic vaccines; and Thermo-Oxidative Stress Induced Antigen(TOSIA) Program that combines chemical engineering, molecular biology, and immunology to discover tumor associated antigens.
Key slides for PDS Biotechnology Corporation


Status Update
PDS Biotechnology Corporation


Status Update
PDS Biotechnology Corporation
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
PDSB
Country
🇺🇸 United States